Berubicin hydrochloride is under clinical development by CNS Pharmaceuticals and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData, Phase II drugs for Glioblastoma Multiforme (GBM) have a 23% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Berubicin hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Berubicin hydrochloride overview
Berubicin hydrochloride (RTA 744) is under development for the treatment of glioblastoma, recurrent glioblastoma multiforme, CNS lymphoma, breast cancer, lung cancer, malignant glioma, pediatric brain tumor, pancreatic cancer, high grade gliomas, ovarian cancer and lymphomas. The drug candidate is an anthracycline derivative. It is a lyophilized drug product administered through intravenous, nasal, vaginal route in the form of powder for solution. It is a potent inhibitor of topoisomerase II. The drug circumvent ATP-binding cassette transporters (multidrug resistance protein 1, breast cancer resistance protein, P-glycoprotein). It was also under development for the treatment of metastatic breast cancer, brain metastasis, anaplastic astrocytoma, anaplastic mixed oligo-astrocytoma, anaplastic oligodendroglioma, neoplastic meningitis (leptomeningeal carcinomatosis) and malignant glioma.
CNS Pharmaceuticals overview
CNS Pharmaceuticals is a clinical-stage pharmaceutical company that develops anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate is Berubicin, a novel anthracycline, the first of its kind to appear to cross the blood-brain barrier. CNS Pharmaceuticals is advancing the development of its WP1244 drug technology, a potent inhibitor of tumor cell proliferation. The company’s products are primarily aimed at treating serious brain and CNS oncology indications, including glioblastoma multiforme, an aggressive form of brain cancer, and pancreatic, ovarian, and lymphomas. The company’s target market includes patients with brain and central nervous system tumors. It serves customers across the US. CNS Pharmaceuticals is headquartered in Houston, Texas, the US.
For a complete picture of Berubicin hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
